The 2026 Surviving Sepsis Campaign guidelines introduce major updates emphasizing earlier recognition and intervention, including standardized screening by EMS before hospital arrival. New ...

An international panel has released the 2026 Surviving Sepsis Campaign guidelines, updating recommendations for managing sepsis and septic shock in adults. The revisions emphasize earlier detection, ...

We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability. If this is not achievable, ...

Sepsis is a medical emergency. Identify early signs, understand the Hour-1 bundle, and see how rapid intervention saves lives ...

The 2 new publications are a major overhaul of sepsis management for adults and children. HealthDay News — International guidelines are presented for the treatment of adults and children with sepsis ...

Vasopressin caught fire as an adjunct vasopressor for sepsis about 20 years ago. The rationale was that septic patients are vasopressin deficient, at least relatively, and they require exogenous ...

With more than 1 million American dying from sepsis annually, providers follow a set of protocols to mitigate a patient’s risk of sepsis. JAMA delves into the updated guidelines, titled Surviving ...

Sepsis, a leading cause of death worldwide, demands a shift from generalized treatment to personalized, predictive, and technology-enabled strategies to improve outcomes globally Sepsis is a ...

Please provide your email address to receive an email when new articles are posted on . ED use of electronic sepsis alert systems significantly reduced sepsis-related mortality. Alert systems improved ...

Both the diagnosis and management of infectious diseases in hospitalized patients remain prominent clinical challenges and are associated with a substantial financial burden for healthcare systems.

Prolonged infusion of beta-lactam antibiotics for sepsis or septic shock tended to improve mortality compared with conventional intermittent infusion in the BLING III trial, and a meta-analysis ...